



U.S. APPLICATION 09/508,570

Clean Version of Amended Claims

21. (Amended) A method for preparing a stabilized multi-component vaccine comprising at least:
- a) pertussis toxoid and filamentous hemagglutinin in purified form,
 - b) tetanus toxoid,
 - c) diphtheria toxoid,
 - d) inactivated polio virus,
 - e) a conjugate of a carrier molecule selected from tetanus toxoid and diphtheria toxoid and a capsular polysaccharide of *Haemophilus influenzae* type B, and
 - f) an aluminum salt,
- wherein tetanus toxoid and diphtheria toxoid are adsorbed onto the aluminum salt before being mixed with the other components and the conjugate is prepared in a phosphate buffer solution before being mixed with the other components.
25. (Amended) The method according to claim 21, further comprising adding hepatitis B surface antigen adsorbed onto an aluminum salt before being mixed with the other components.
26. (Amended) The method according to claim 21, wherein mixing is conducted in the following order:
- a) adsorbing tetanus toxoid and diphtheria onto aluminum hydroxide,
 - b) adsorbing pertussis toxoid and filamentous hemagglutinin in purified form onto an aluminum salt,
 - c) mixing the components obtained in a) with those obtained in b),
 - d) adding inactivated polio virus,
 - e) adding a phosphate buffer solution of a conjugate of a carrier molecule selected from tetanus toxoid and diphtheria toxoid and a capsular polysaccharide of *Haemophilus influenzae* type B.
27. (Amended) A method according to claim 25 wherein mixing is conducted in the following order:
- a) adsorbing tetanus toxoid and diphtheria onto aluminum hydroxide,

- b) adsorbing pertussis toxoid and filamentous hemagglutinin in purified form onto an aluminum salt,
- c) mixing the components obtained in a) with those obtained in b),
- d) adding inactivated poliovirus after c),
- e) adding hepatitis B surface antigen previously adsorbed onto an aluminum salt after d),
- f) adding a phosphate buffer solution of a conjugate of a carrier molecule selected from tetanus toxoid and diphtheria toxoid and a capsular polysaccharide of *Haemophilus influenzae* type B after e).

34. (Amended) A multi-component vaccine obtained by the method of claim 27, wherein the composition of said vaccine comprises per 0.5 ml dose:

- g) 25 µg pertussis toxoid;
- h) 25 µg filamentous hemagglutinin;
- i) 30 LF diphtheria toxoid;
- j) 10 Lf tetanus toxoid;
- k) 40 D antigen units poliovirus type 1;
- l) 8 D antigen units poliovirus type 2;
- m) 32 D antigen units poliovirus type 3;
- n) 10 µg *Haemophilus influenzae* type B polysaccharide covalently bound to 20 µg tetanus toxoid; and
- o) 5 µg hepatitis B surface antigen.

36. (Amended) A method for conferring protection in a host against disease caused by *Bordetella pertussis*, *Clostridium tetanii*, *Corynebacterium diphtheriae*, *Haemophilus influenzae*, *Poliovirus* and/or *Hepatitis B virus* using a multi-component vaccine obtained by the method of claim 27.

37. (Amended) A method of immunizing a human host against disease caused by infection by *Bordetella pertussis*, *Clostridium tetanii*, *Corynebacterium diphtheriae*, *Haemophilus*

influenzae, *Poliovirus*, and/or *Hepatitis B virus*, which method comprises administering to the host a multi-component vaccine obtained by the method of claim 27.